Clinical Trials

Confirmatory Phase III Clinical Study

DIA-AID 2 (DiaPep277^® - Arresting Immune Diabetes)

DIA-AID 2 is a confirmatory phase III study which began in the first half of 2010. This study is a global clinical trial which will be conducted in Europe, USA, Israel, and Latin America with approximately 450 patients being recruited at more than 100 clinical study sites.

To be eligible for the study, potential patients should be between 20 to 45 years of age and within 6 months of diagnosis of type 1 diabetes. Furthermore, the study requires a residual beta cell function when fasting of C-peptide ≥ 0.2nmol/L.

Patients will be randomized to 1.0 mg DiaPep277^® or placebo with primary endpoint beta cell preservation of function.

Study Steering Committee

Prof. Itamar Raz
Hadassah Medical Center
Jerusalem, Israel
Prof. Paolo Pozzilli
Università Campus Bio-Medico di Roma
Rome, Italy
Prof. Thomas Linn
Universitätsklinikum Giessen
Giessen, Germany
Prof. Francois Bonnici
New Groote Schuur Hospital
Capetown, South Africa
Prof. Philip Raskin
University of Texas Southwestern Medical Center at Dallas
Dallas, Texas
USA